Preclinical Research
Comparison of Toxicology Assessment Baseline Data Collected Using Two Restraint Methods in Nonhuman Primates: Restraint Chair/Pole and Collar vs. Procedure Cage
Downsized Sinclair™ vs. Göttingen™ Minipigs Similarities and Differences of Toxicological Reference Range Data in Preclinical Safety Studies
Ocular Imaging and Microscopic Analysis of Focal Chorioretinal Defects in Rabbits
Validation of an SC5b-9 Commercial Kit for Preclinical Biomarker Analysis
Correlating Changes in Body Weights and Immune System Parameters in Cynomolgus Macaques
Scratching the Surface of Dermal Testing
Avoid These Mistakes During Formulation for Nonclinical Testing
Improve Your Odds of Success
Formulation development is a critical step that ensures the drug product is produced safely and effectively for use in nonclinical testing and, eventually, in clinical trials. Solubility, stability, route of administration, and dosage frequency are some of the factors assessed during formulation development.
In this podcast, our scientific experts discuss the everyday challenges encountered in formulation development for nonclinical testing, and tips to avoid or mitigate them to facilitate your IND application.
Do you need your API formulated and manufactured for nonclinical testing? Contact us today to get started!
Related Resources:
- Webpage: Contract Manufacturing and Analytical Solutions
- Interview: Complex and Customized Formulation Development
- Podcast: Key Considerations as You Move From Discovery to Preclinical to Clinical
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Nonclinical Considerations for Ophthalmic Drug Development
Ophthalmic drug development comes with a unique set of challenges and complexities. To maximize your chance of success, it is best to rely on a drug development partner with regulatory knowledge, scientific and technical expertise, and a thorough understanding of the market in this growing therapeutic area.
In our latest podcast episode, learn about the key considerations for developing your ocular safety assessment program, including selecting the right animal model.
Altasciences’ clients benefit from working with a single CRO/CDMO partner, from prototype formulation through preclinical testing, to early phase clinical trials, and manufacturing. This could mean up to 40% in both time and cost savings.
Have questions? Speak with one of our experts.
You might also be interested in:
- The Altascientist: The Complexities of Early Phase Ophthalmic Drug Development
- Webpage: End-to-End Ophthalmology Solutions
- Fact Sheet: Comprehensive Services for Ophthalmic Drug Development
Ophthalmic End-to-End Drug Development Solutions